---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-081485"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T13:26:33.206164+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics reports FY2022 net loss of $48.6M; cash runway into H2 2025

## Summary
- Net loss $48.6M vs $36.8M in 2021; loss per share $1.58.
- Cash and securities $107.1M at Dec 31, 2022, down from $147.6M.
- IND submitted for lead candidate SNS-101 (VISTA-blocking antibody) in March 2023.
- New collaborations with Regeneron, NCI, and WashU to support SNS-101 development.
- Expects to select candidates for SNS-102 and SNS-103 in 2023; cash runway into H2 2025.

## SEC filing metadata
- accession: 0001193125-23-081485
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312523081485/0001193125-23-081485-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312523081485/d466084d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-081485
- JSON: https://secwatch.observer/filing/0001193125-23-081485.json
- Plain text: https://secwatch.observer/filing/0001193125-23-081485.txt

## Key facts
- Earnings Releases
  Sensei Biotherapeutics, Inc. reported financial results for the full year ended December 31, 2022.
  - Period: the full year ended December 31, 2022
  - Result: reported results
  source text: On March 28, 2023, Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312523081485/0001193125-23-081485-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.